Clinical trials recruiting for Unresectable Malignant Solid Neoplasm
8
Recruiting trials
45
US states with sites
2
Countries
0%
Accept healthy volunteers
Phase breakdown
Phase 1 7Phase 2 2
Drugs and treatments being studied
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| California | 5 |
| Massachusetts | 5 |
| Florida | 4 |
| Missouri | 4 |
| Pennsylvania | 4 |
| Texas | 4 |
| Illinois | 3 |
| Ohio | 3 |
| Kentucky | 2 |
| New York | 2 |
| Oklahoma | 2 |
| Tennessee | 2 |
Top cities
Boston, Massachusetts 5Houston, Texas 4Pittsburgh, Pennsylvania 4St Louis, Missouri 4Gainesville, Florida 3Orange, California 3Sacramento, California 3Chicago, Illinois 2Cincinnati, Ohio 2City of Saint Peters, Missouri 2
Self-screener
Recruiting trials
- Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
- TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
- Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
- Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
- Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
- Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
Related conditions
Trials recruiting for Unresectable Malignant Solid Neoplasm often also study these conditions. Each links to its own recruiting-trial list.
Metastatic Malignant Solid Neoplasm 21Breast cancer 2239Anatomic Stage IV Breast Cancer AJCC v8 43Anatomic Stage III Breast Cancer AJCC v8 39Advanced Malignant Solid Neoplasm 13Unresectable Triple-Negative Breast Carcinoma 5Unresectable Pancreatic Adenocarcinoma 4Unresectable Breast Carcinoma 3Triple-Negative Breast Carcinoma 10Stage IV Pancreatic Cancer AJCC v8 19
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Unresectable Malignant Solid Neoplasm trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.